Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis.

Melissa SorosinaF ClarelliL FerrèA M OsiceanuN T UnalE MasciaV MartinelliG ComiF BenigniFederica EspositoF Martinelli Boneschi

Published in: European journal of neurology (2018)

Our findings support the immunomodulatory activity of cannabinoids in patients with MS. Further studies in more specific cell types are needed to refine these results.

Keyphrases

multiple sclerosis
single cell
mass spectrometry
cell therapy
cell proliferation
ms ms
case control
stem cells
mesenchymal stem cells